2023
Hospitalisations for heart failure: increased palliative care referrals − a veterans affairs hospital initiative
Gruen J, Gandhi P, Gillespie-Heyman S, Shamas T, Adelman S, Ruskin A, Bauer M, Merchant N. Hospitalisations for heart failure: increased palliative care referrals − a veterans affairs hospital initiative. BMJ Supportive & Palliative Care 2023, 14: e1309-e1316. PMID: 36609533, DOI: 10.1136/spcare-2022-004118.Peer-Reviewed Original ResearchHeart failurePalliative careHF admissionsMedian B-type natriuretic peptideB-type natriuretic peptidePalliative care referralCare educationVeterans Affairs hospitalPercentage of referralsStudy-Act cyclesQuality of lifeMultiple PDSA cyclesPg/mLPC consultHF managementHF patientsBaseline medianCare referralHospital InitiativeReferral guidelinesSignificant morbidityNatriuretic peptideMean ageNew referralsReferral criteria
2015
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF
2014
Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study
Gandhi PU, Szymonifka J, Motiwala SR, Belcher AM, Januzzi JL, Gaggin HK. Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal Of Cardiac Failure 2014, 21: 9-15. PMID: 25463415, DOI: 10.1016/j.cardfail.2014.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersCardiovascular AgentsChronic DiseaseDisease ManagementDizzinessFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsProspective StudiesQuality of LifeRenal InsufficiencySurveys and QuestionnairesTreatment OutcomeConceptsTreatment-related serious adverse eventsSerious adverse eventsQuality of lifeAdverse eventsRisk scoreN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic heart failure managementHeart Failure Questionnaire scoreWorse QOLAcute renal failureFirst cardiovascular eventHeart failure managementHeart failure therapyWorse functional classHighest-risk quartileCare armHF careHF managementSystolic HFCardiovascular eventsNT-proBNPReverse remodelingFailure therapyRenal failure